Iveric Bio to Host Investor Symposium on Dry AMD

Source: Iveric bio

Iveric bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium for investors and analysts being held on Friday, June 18, 2021 from 10 am to 12 pm Eastern Time. The symposium will include presentations on the company’s Zimura (avacincaptad pegol) pivotal program in geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an update on patient enrollment and retention in the Zimura GATHER2 clinical trial, the dry AMD landscape, and highlights on the company’s HtrA1 inhibitor, IC-500, in AMD.

Iveric bio also announced that a presentation by Vas Sadda, MD, Doheny Eye Institute UCLA, will feature new post-hoc analyses from the GATHER1 clinical trial on progression of drusen and nascent GA, which are earlier forms of dry AMD, in patients treated with Zimura as compared to patients in the sham group. 

The company will host discussions with retinal specialists and key opinion leaders.  Participants include:

  • Frank Holz, FEBO, FARVO, University of Bonn
  • Peter Kaiser, MD, Cole Eye Institute
  • Arshad Khanani, MD, MA, Sierra Eye Associates
  • Anat Loewenstein, MD, Tel Aviv University
  • Vas Sadda, MD, Doheny Eye Institute UCLA
  • Trent Woodruff, PhD, The University of Queensland
  • Charles Wykoff, MD, PhD, Retina Consultants of Texas
  • Dhaval Desai, PharmD, Chief Development Officer, Iveric Bio
  • Pravin Dugel, MD, President, Iveric Bio
  • Glenn Sblendorio, Chief Executive Officer, Iveric Bio

Related Content